Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer

Open access
Baselga, José, Segalla, José Getúlio Martins, Roché, Henri, del Giglio, Auro, Pinczowski, Hélio, Ciruelos, Eva M., Filho, Sebastião Cabral, Gómez, Patricia, Van Eyll, Brigitte, Bermejo, Begoña, Llombart, Antonio, Garicochea, Bernardo, Durán, Miguel Ángel Climent, Hoff, Paulo Marcelo Gehm, Espié, Marc, de Moraes, Andre Augusto Junior Gemeinder, Ribeiro, Ronaldo Albuquerque, Mathias, Clarissa, Gil Gil, Miguel, Ojeda, Belén, Morales, Josefa, Kwon Ro, Sunhee, Li, Shell, Costa, Frederico·2012·Journal of Clinical Oncology

Abstract

Purpose: Sorafenib is a multikinase inhibitor with antiangiogenic/antiproliferative activity. A randomized, double-blind, placebo-controlled phase IIB trial assessed sorafenib with capecitabine for locally advanced or metastatic human epidermal growth factor receptor 2 (HER2) –negative breast cancer. Patients and Methods: Patients were randomly assigned to first- or second-line capecitabine 1,000 mg/m 2 orally twice a day for days 1 to 14 of every 21-day cycle with sorafenib 400 mg orally twice a day or placebo. The primary end point was progression-free survival (PFS). Results: In total, 229 patients were enrolled. The addition of sorafenib to capecitabine resulted in a significant improvement in PFS versus placebo (median, 6.4 v 4.1 months; hazard ratio [HR], 0.58; 95% CI, 0.41 to 0.81; P = .001) with sorafenib favored across subgroups, including first-line (HR, 0.50; 95% CI, 0.30 to 0.82) and second-line (HR, 0.65; 95% CI, 0.41 to 1.04) treatment. There was no significant improvement for overall survival (median, 22.2 v 20.9 months; HR, 0.86; 95% CI, 0.61 to 1.23; P = .42) and overall response (38% v 31%; P = .25). Toxicities (sorafenib v placebo) of any grade included rash (22% v 8%), diarrhea (58% v 30%), mucosal inflammation (33% v 21%), neutropenia (13% v 4%), hypertension (18% v 12%), and hand-foot skin reaction/hand- foot syndrome (HFSR/HFS; 90% v 66%); grade 3 to 4 toxicities were comparable between treatment arms except HFSR/HFS (44% v 14%). Reasons for discontinuation in the sorafenib and placebo arms included disease progression (63% v 82%, respectively), adverse events (20% v 9%, respectively), and death (0% v 1%, respectively). Conclusion: Addition of sorafenib to capecitabine improved PFS in patients with HER2-negative advanced breast cancer. The dose of sorafenib used in this trial resulted in unacceptable toxicity for many patients. A phase III confirmatory trial has been initiated with a reduced sorafenib dose.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2011.36.7771

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 164

Metadata

Authors
Baselga, J., Segalla, J. G. M., Roché, H., del Giglio, A., Pinczowski, H., Ciruelos, E. M., Filho, S. C., Gómez, P., Van Eyll, B., Bermejo, B., Llombart, A., Garicochea, B., Durán, M. Á. C., Hoff, P. M. G., Espié, M., de Moraes, A. A. J. G., Ribeiro, R. A., Mathias, C., Gil Gil, M., Ojeda, B., Morales, J., Kwon Ro, S., Li, S., & Costa, F.
Venue
Journal of Clinical Oncology
Published
2012-05-01
Volume
30
Issue
13
Pages
1484-1491
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2131528383
Cited by
164
References
1
FWCI
8.48
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. https://app.cochat.ai/papers/10.1200/jco.2011.36.7771
The paper
Baselga, J., Segalla, J. G. M., Roché, H., del Giglio, A., Pinczowski, H., Ciruelos, E. M., Filho, S. C., Gómez, P., Van Eyll, B., Bermejo, B., Llombart, A., Garicochea, B., Durán, M. Á. C., Hoff, P. M. G., Espié, M., de Moraes, A. A. J. G., Ribeiro, R. A., Mathias, C., Gil Gil, M., . . . Costa, F. (2012). Sorafenib in Combination With Capecitabine: An Oral Regimen for Patients With HER2-Negative Locally Advanced or Metastatic Breast Cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2011.36.7771

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.